sorafenib has been researched along with B-Cell Chronic Lymphocytic Leukemia in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 9 (90.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fan, L; Han, TT; Li, JY; Xu, W | 1 |
| Bil, J; Bobrowicz, M; Bojarczuk, K; Dwojak, M; Giannopoulos, K; Golab, J; Lech-Maranda, E; Malenda, A; Pyrzynska, B; Siernicka, M; Tomczak, W; Winiarska, M | 1 |
| Andreeff, M; Borthakur, G; Cortes, JE; Faderl, S; Kantarjian, H; Konopleva, M; Mathews, S; Ravandi, F; Verstovsek, S; Wright, JJ; Zhang, W | 1 |
| Bharati, IS; Fecteau, JF; Handel, TM; Kipps, TJ; Messmer, D; O'Hayre, M | 2 |
| Decker, T; Huber, S; Kuhnt, T; Lutzny, G; Oelsner, M; Oostendorp, RA; Peschel, C; Ringshausen, I; Schmidt, B; Wagner, M; zum Büschenfelde, CM | 1 |
| Aymerich, M; Campo, E; Colomer, D; López-Guerra, M; Montserrat, E; Pérez-Galán, P; Rosich, L; Roué, G; Saborit-Villarroya, I; Villamor, N; Xargay-Torrent, S | 1 |
| Claasen, J; Frenzel, LP; Gehrke, I; Hallek, M; Krause, G; Kuckertz, M; Patz, M; Veldurthy, A; Wendtner, CM | 1 |
| Bühler, A; Döhner, H; Jebaraj, BM; Kienle, D; Stilgenbauer, S; Winkler, D; Zenz, T | 1 |
| Bargetzi, M; Puric, E; Schönenberger, A; Sendi, P | 1 |
1 review(s) available for sorafenib and B-Cell Chronic Lymphocytic Leukemia
| Article | Year |
|---|---|
Role of chemokines and their receptors in chronic lymphocytic leukemia: function in microenvironment and targeted therapy.
Topics: Aminopyridines; Antineoplastic Agents; Benzylamines; Chemokine CXCL12; Clinical Trials as Topic; Cyclams; Dasatinib; Heterocyclic Compounds; Humans; Lenalidomide; Leukemia, Lymphocytic, Chronic, B-Cell; Molecular Targeted Therapy; Morpholines; Niacinamide; Oxazines; Phenylurea Compounds; Protein Kinase Inhibitors; Purines; Pyridines; Pyrimidines; Quinazolinones; Receptors, CXCR4; Sorafenib; Thalidomide; Thiazoles; Tumor Microenvironment | 2014 |
1 trial(s) available for sorafenib and B-Cell Chronic Lymphocytic Leukemia
| Article | Year |
|---|---|
Phase I study of sorafenib in patients with refractory or relapsed acute leukemias.
Topics: Adult; Aged; Aged, 80 and over; Benzenesulfonates; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prognosis; Protein Kinase Inhibitors; Pyridines; Remission Induction; Salvage Therapy; Sorafenib; Survival Rate; Young Adult | 2011 |
8 other study(ies) available for sorafenib and B-Cell Chronic Lymphocytic Leukemia
| Article | Year |
|---|---|
Sorafenib improves rituximab and ofatumumab efficacy by decreasing the expression of complement regulatory proteins.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal, Murine-Derived; Complement System Proteins; Gene Expression Regulation, Leukemic; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Niacinamide; Phenylurea Compounds; Rituximab; Sorafenib | 2015 |
Chronic lymphocytic leukemia cells receive RAF-dependent survival signals in response to CXCL12 that are sensitive to inhibition by sorafenib.
Topics: Apoptosis; Benzenesulfonates; Calcium; Cell Survival; Chemokine CXCL12; Dose-Response Relationship, Drug; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Flow Cytometry; Humans; Immunoblotting; Intracellular Space; Jurkat Cells; Leukemia, Lymphocytic, Chronic, B-Cell; Mitogen-Activated Protein Kinases; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Pyridines; raf Kinases; Receptors, CXCR4; Signal Transduction; Sorafenib; Time Factors; Tumor Cells, Cultured; ZAP-70 Protein-Tyrosine Kinase | 2011 |
Sorafenib induces cell death in chronic lymphocytic leukemia by translational downregulation of Mcl-1.
Topics: Antineoplastic Agents; Apoptosis; Benzenesulfonates; Flow Cytometry; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Specific Protein Tyrosine Kinase p56(lck); Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Phosphorylation; Proto-Oncogene Proteins c-bcl-2; Pyridines; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; RNA, Small Interfering; Sorafenib; Stromal Cells; Tumor Cells, Cultured | 2011 |
Sorafenib-induced apoptosis of chronic lymphocytic leukemia cells is associated with downregulation of RAF and myeloid cell leukemia sequence 1 (Mcl-1).
Topics: Apoptosis; Benzenesulfonates; Cell Survival; Cells, Cultured; Humans; Immunoblotting; Leukemia, Lymphocytic, Chronic, B-Cell; Myeloid Cell Leukemia Sequence 1 Protein; Niacinamide; Phenylurea Compounds; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-raf; Pyridines; raf Kinases; Sorafenib; Tumor Cells, Cultured | 2012 |
Sorafenib targets BCR kinases and blocks migratory and microenvironmental survival signals in CLL cells.
Topics: Benzenesulfonates; Blotting, Western; Cell Movement; Cell Survival; Chemokines; Chemotaxis; Humans; Intracellular Signaling Peptides and Proteins; Leukemia, Lymphocytic, Chronic, B-Cell; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Real-Time Polymerase Chain Reaction; Receptors, Antigen, B-Cell; RNA, Messenger; Sorafenib; src-Family Kinases; Syk Kinase; Tumor Cells, Cultured; Tumor Microenvironment | 2012 |
Comparison of the effects of two kinase inhibitors, sorafenib and dasatinib, on chronic lymphocytic leukemia cells.
Topics: Benzenesulfonates; Cell Survival; Dasatinib; Dose-Response Relationship, Drug; Humans; Lethal Dose 50; Leukemia, Lymphocytic, Chronic, B-Cell; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Sorafenib; Thiazoles; Treatment Outcome; Tumor Cells, Cultured | 2012 |
BRAF mutations in chronic lymphocytic leukemia.
Topics: Antineoplastic Agents; Apoptosis; Exons; Extracellular Signal-Regulated MAP Kinases; Humans; Indoles; Leukemia, Lymphocytic, Chronic, B-Cell; Mitogen-Activated Protein Kinases; Mutation; Niacinamide; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Signal Transduction; Sorafenib; Sulfonamides; Treatment Outcome | 2013 |
[Chronic lymphocytic leukemia and loss of strength in the right arm--not a typical combination].
Topics: Administration, Oral; Aged; Antineoplastic Agents; Arm; Benzenesulfonates; Bone Neoplasms; Carcinoma, Renal Cell; Clinical Trials, Phase III as Topic; Disease Progression; Humans; Hypesthesia; Indoles; Kidney Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Liver Neoplasms; Lung Neoplasms; Magnetic Resonance Imaging; Male; Muscle Weakness; Neoplasms, Second Primary; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Radiography, Abdominal; Radiography, Thoracic; Risk; Risk Factors; Sex Factors; Sorafenib; Splenic Neoplasms; Sunitinib; Time Factors; Tomography, X-Ray Computed | 2007 |